Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy in a Multicenter Cohort of Patients With Refractory Ulcerative Colitis.

NCT05728008 · clinicaltrials.gov ↗
COMPLETED
Status
100
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

IRCCS San Raffaele